The diagnostics firm forecasts 31% revenue growth excluding true-ups, driven by record test volumes and oncology momentum.
Natera set a 2026 revenue outlook of $2.85 billion to $2.91 billion, reflecting 31% growth excluding true-ups. The company processed 1.04 million tests in Q2 2026, a new record, with oncology tests rising 56% year-over-year.
In Q2 2026, Natera reported 283,000 clinical minimal residual disease (MRD) units, marking its largest sequential increase to date. The growth was attributed to expanding oncology demand and operational scaling.
Management highlighted strong momentum in its core segments, reinforcing confidence in the long-term revenue trajectory.